%PDF-1.4
%
50 0 obj
<>
endobj
47 0 obj
<>
endobj
190 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T18:16:09Z
2024-03-29T00:45:48-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:45:48-07:00
application/pdf
Heather
201111.omeract
uuid:a8b48f78-1dd1-11b2-0a00-e708277d8900
uuid:a8b48f7a-1dd1-11b2-0a00-d30000000000
endstream
endobj
36 0 obj
<>
endobj
37 0 obj
<>
endobj
51 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
16 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
222 0 obj
[227 0 R]
endobj
223 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
55 54 m
559 54 l
S
/CS0 cs 0 0 0 0 scn
/GS0 gs
103.25 57.17 407.5 -10.83 re
f*
Q
Q
q
1 0 0 1 0 1 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
103.25 57.17 407.5 -10.83 re
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.0249 Tw 8 0 0 8 54.5 35.9844 Tm
[(W)92 (oodworth, et al: Standar)37 (dizing assessment in RA)]TJ
0 Tw 60.9375 -0.0313 Td
(1169)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw -61.05 84.0995 Td
[(Peripheral sensory)-2193 (Subjective symptoms without)-3483 (Objective sensory loss,)-4662 (Prolonged sensory loss or)-7486 (\227)]TJ
0 -1.25 TD
[(neuropathy)-4608 (objective findings, transient, not)-2541 (persistent, not interfering)-3747 (paresthesias interfering with)]TJ
T*
[(\(sensory disturbance\))-2057 (interfering with function)-6468 (with function)-10141 (function)]TJ
T*
[(Seizure)-12102 (\227)-8246 (Recurrence of old seizures)-4651 (Repetitive with partial )-5907 (New seizure)]TJ
0 Tc 39.5655 -1.25 Td
(response to medication)Tj
-0.00011 Tc -39.5655 -1.25 Td
[(V)111 (ertigo \(dizziness\))-1639 (Subjective symptoms, transient,)-1776 (Objective findings, recurrent,)-1983 (Persistent, prolonged, interfering)-6069 (\227)]TJ
0 Tc 10.4795 -1.25 Td
[(intermittent, no treatment)-3665 (meds relieve, occasionally)-2611 (with daily function; partial or no)]TJ
-0.00011 Tc 14.2808 -1.25 Td
[(interfering with function)-6092 (response to meds)]TJ
/TT2 1 Tf
-24.7603 -2.5 Td
[(Abnormal laboratory test r)18 (esults \(with associated consequences\))]TJ
0 Tw T*
(Hematology)Tj
/TT1 1 Tf
0.02499 Tw T*
(Hb \(g/dl\) decrease)Tj
0 Tc T*
[(from pretreatment)-6829 (1.0\2261.4)-11100 (1.5\2262.0)-7570 (2.1\2262.9; or Hb < 8.0, > 7.0)]TJ
/C2_0 1 Tf
0 Tw 53.7148 0 Td
<0095>Tj
/TT1 1 Tf
0.02499 Tw 0.8238 0 Td
(3.0; or Hb < 7.0)Tj
-54.5387 -1.25 Td
[(Leukopenia \(total )18 (WBC\) )]TJ
/T1_0 1 Tf
0 Tw 10.2481 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw 0.8238 0 Td
[(1000)-1028 (3.0\2263.9)-11100 (2.0\2262.9)-11500 (1.0\2261.9)-10630 (< 1.0)]TJ
-0.00011 Tc -11.0719 -1.25 Td
(Neutropenia \()Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.1 (\002\001)]TJ
/TT1 1 Tf
0 Tc 0.02499 Tw 6.3735 0 Td
[(1000\))-5394 (1.5\2261.9)-11100 (1.0\2261.4)-11500 (0.5\2260.9)-10630 (< 0.5)]TJ
-6.3735 -1.25 Td
[(L)55 (ymphopenia \()]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 6.382 0 Td
(\002\001)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 0.8238 0 Td
[(1000\))-4561 (1.5\2261.9)-11100 (1.0\2261.4)-11500 (0.5\2260.9)-10630 (< 0.5)]TJ
-0.00011 Tc -7.2059 -1.25 Td
(Platelets \()Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw [0.2 (\002\001)]TJ
/TT1 1 Tf
0 Tc 0.0249 Tw 5.0943 0 Td
(1000\))Tj
8.784 0 Td
(75\226LLN)Tj
14.197 0 Td
(50\22674.9)Tj
8.59 0 Td
[(20\22649.9; platelet transfusion required)-2640 (< 20; recurrent)]TJ
-0.00011 Tc 16.6849 -1.25 Td
(platelet transfusions)Tj
/TT2 1 Tf
-0.0002 Tc 0 Tw -53.3502 -2.5 Td
(Chemistry)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw T*
[(Hypercalcemia \(mg/dl\))-2966 (1.1 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 13.8167 0 Td
(\002\001)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 0.8238 0 Td
[(ULN\2261)37 (1.5)-8810 (1)37 (1.6\22612.5)-6051 (12.6\22613.5; or symptoms present)-1308 (> 13.5; or associated coma)]TJ
-14.6405 -1.25 Td
[(Hyper)18 (glycemia \(mg/dl\),)-4180 (140\226160)-10600 (161\226250)-11000 (251\226500)-6496 (>500, or associated with)]TJ
-0.00011 Tc 0 Tw T*
(fasting)Tj
0 Tc 54.9036 0 Td
(ketoacidosis)Tj
0.02499 Tw -54.9036 -1.25 Td
[(Hyperkalemia \(mEq/l\))-5052 (5.5\2265.9)-11100 (6.0\2266.4)-7396 (6.5\2267.0 or any ECG change)-2782 (> 7.0 or any arrhythmia)]TJ
T*
[(Hypocalcemia \(mg/dl\))-3393 (0.9 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 14.2413 0 Td
(\002\001)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 0.8238 0 Td
[(LLN\2267.8)-9441 (7.7\2267.0)-7589 (6.9\2266.5; or associated with)-3157 (< 6.5, or occurrence of)]TJ
-0.00011 Tc 0 Tw 27.0792 -1.25 Td
[(symptoms)-9898 (tetany)]TJ
0 Tc 0.0249 Tw -42.1443 -1.25 Td
[(Hypoglycemia \(mg/dl\))-2026 (55\22664 \(no symptoms\))-3776 (40\22654 \(or symptoms present\))-1567 (30\22639 \(symptoms impair function\))-3334 (< 30, or coma)]TJ
T*
[(Hyponatremia \(mEq/l\))-5995 (\227)-11850 (125\226129)-11000 (120\226124)-10255 (< 120)]TJ
T*
[(Hypokalemia \(mEq/l\))-6328 (\227)-12100 (3.0\2263.4)-11500 (2.5\2262.9)-10630 (< 2.5)]TJ
-0.00011 Tc T*
[(CPK)-250 (\(also if polymyositis-)-1725 (1.2\2261.9 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 16.0733 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
[(ULN)-7534 (2.0\2264.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 13.1387 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
[(ULN)-5448 (> 4.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw (\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 10.965 0 Td
[(ULN with weakness)-1833 (> 4.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 12.6851 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 0.8238 0 Td
(ULN with signs or)Tj
-55.3335 -1.25 Td
(like disease\))Tj
0 Tc 38.677 0 Td
[(but without life-threatening)-2461 (symptoms of rhabdomyo-)]TJ
0 Tw -38.677 -1.25 Td
(.)Tj
-0.00011 Tc 0.02499 Tw 40.4251 0 Td
[(signs or symptoms)-4711 (lysis or life-threatening)]TJ
-40.4251 -1.25 Td
[(Serum uric acid)-6005 (1.2\2261.6 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 15.9357 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
[(ULN)-7672 (1.7\2262.9 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.1 0 Td
[(ULN)-4048 (3.0\2265.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 9.6527 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 0.8238 0 Td
[(ULN or gouty symptoms)-5437 (\227)]TJ
0 Tc -41.3361 -1.25 Td
[(Creatinine \(mg/dl\))-4947 (1.1\2261.3 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 15.9357 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
[(ULN)-7672 (1.3\2261.8 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.1 0 Td
[(ULN)-8072 (1.9\2263.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.5 0 Td
[(ULN)-7202 (> 3.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
12.7194 0 Td
(ULN)Tj
-0.00011 Tc 0.0251 Tw -58.0791 -1.25 Td
[(SGOT)-257 (\(AST\))-6964 (1.2\2261.5 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 16.7595 0 Td
[(ULN)-7672 (1.6\2263.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.1 0 Td
[(ULN)-8072 (3.1\2268.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.5 0 Td
[(ULN)-7202 (> 8.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
12.7194 0 Td
(ULN)Tj
-0.00011 Tc 0.0251 Tw -58.0791 -1.25 Td
[(SGPT)-257 (\(AL)92 (T\))-7167 (1.2\2261.5 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 16.7595 0 Td
[(ULN)-7672 (1.6\2263.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.1 0 Td
[(ULN)-8072 (3.0\2268.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.3 (\002\001)]TJ
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 14.5 0 Td
[(ULN)-7202 (> 8.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
12.7194 0 Td
(ULN)Tj
0 Tc 0.02499 Tw -58.0791 -1.25 Td
[(Alkaline phosphatase)-4568 (1.1\2262.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw 16.4482 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
[(ULN)-7472 (1.6\2263.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 12.8012 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
[(ULN)-7847 (3.0\2265.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 13.1762 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
[(ULN)-6927 (> 5.0 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
12.1694 0 Td
(ULN)Tj
0 Tc 0.02499 Tw -57.0666 -1.25 Td
[(T)74 (. bilirubin)]TJ
13.17399 0 Td
(1.1\2261.4 )Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw 3.27421 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
(ULN)Tj
9.52668 0 Td
(1.5\2261.9 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.27452 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
(ULN)Tj
9.90168 0 Td
(2.0\2263.0 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.27452 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
(ULN)Tj
8.98168 0 Td
(> 3.0 )Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.4 (\002\001)]TJ
/TT1 1 Tf
3.18772 0 Td
(ULN)Tj
-0.00011 Tc -57.0666 -1.25 Td
(LDH)Tj
13.17368 0 Td
(1.3\2262.4 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.27452 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
(ULN)Tj
9.52668 0 Td
(2.5\2265.0 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.27452 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
(ULN)Tj
10.02668 0 Td
(5.1\22610 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.02452 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.0251 Tw 0.8238 0 Td
(ULN)Tj
9.23168 0 Td
(> 10 )Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.2 (\002\001)]TJ
/TT1 1 Tf
2.93772 0 Td
(ULN)Tj
/TT2 1 Tf
-0.00011 Tc -56.9415 -2.5 Td
(Urinalysis)Tj
/TT1 1 Tf
0.02499 Tw T*
(Hematuria)Tj
14.00204 0 Td
(Micro only)Tj
12.86192 0 Td
(Gross, no clots)Tj
11.55339 0 Td
[(Clots, transfusion < 2 units)-2801 (T)35 (ransfusions required)]TJ
0 Tc -38.41735 -1.25 Td
[(Proteinuria \(per 24 h\))-3956 (300\226500 g \(tr/1+\))]TJ
26.48797 0 Td
[(501\2261999 g \(2+\))-3961 (2\2265.0 g \(3+\) nephrotic syndrome)-1683 (> 5.0 g \(4+\) anasarca)]TJ
-26.48797 -1.25 Td
(WBC in urine)Tj
15.75099 0 Td
(\227)Tj
13.625 0 Td
(\227)Tj
7.229 0 Td
[(Indicating acute interstitial nephritis)-942 (Associated with acute)]TJ
-0.00011 Tc 17.45391 -1.25 Td
(renal failure)Tj
-54.0589 -1.25 Td
[(Uric acid crystals)-3874 (Present without symptoms)]TJ
29.37449 0 Td
(\227)Tj
7.44489 0 Td
[(W)40 (ith stones or symptoms of stones)-1102 (Causing renal outflow)]TJ
0 Tc 3.63012 -1.25 Td
[(\(e.g., renal colic\))-3009 (obstruction and hospitalization)]TJ
/TT2 1 Tf
-0.00011 Tc -40.4495 -2.5 Td
[(Autoimmune syndr)18 (omes, if not part of basic disease)]TJ
/TT1 1 Tf
0 Tc T*
[(ANA)-220 (\(see also SLE-like)-1823 (Appearance of positive)-3662 (1:160\2261:320 or equivalent)-4366 (> 1:320 or equivalent)]TJ
56.00795 0 Td
(\227)Tj
-0.00011 Tc -56.00794 -1.25 Td
(disease\))Tj
10.86815 0 Td
[(ANA)-220 (to 1:80 or equivalent)]TJ
-10.86815 -1.25 Td
[(dsDNA)-220 (\(see also SLE-)-2433 (Appearance of positive)]TJ
27.1726 0 Td
(2\2263.9 )Tj
/T1_0 1 Tf
-0.0002 Tc 0 Tw 2.5256 0 Td
(\002\001)Tj
/TT1 1 Tf
-0.00011 Tc 0.8238 0 Td
(ULN)Tj
10.27668 0 Td
(4.0\2268.0 )Tj
/T1_0 1 Tf
-0.0002 Tc 3.27452 0 Td
(\002\001)Tj
/TT1 1 Tf
0.8238 0 Td
(ULN)Tj
11.1024 0 Td
(\227)Tj
-0.00011 Tc 0.02499 Tw -55.9995 -1.25 Td
(like disease\))Tj
12.25961 0 Td
[(dsDNA)-220 (to 2 )]TJ
/T1_0 1 Tf
-0.0002 Tc 0 Tw [-0.5 (\002\001)]TJ
/TT1 1 Tf
5.92619 0 Td
(ULN)Tj
0 Tc 0.02499 Tw -18.1859 -1.25 Td
[(Anti-choline receptor )55 (AB)]TJ
15.75199 0 Td
(\227)Tj
8.99201 0 Td
(Appearance of antibodies)Tj
18.63599 0 Td
(\227)Tj
12.625 0 Td
(\227)Tj
-0.00011 Tc -56.00497 -1.25 Td
(\(see weakness\))Tj
0 Tc 0.0925 Tw 0 -2.5 TD
[(Meds: medication\(s\); OTC: over)20 (-the-counter medication; )55 (ADL: activities of daily living; iv: intravenous; ECG: electrocardiogram\
)13.1 (; CHF: congestive heart)]TJ
-0.034 Tw 0 -1.25 TD
[(failure; MRI: magnetic resonance imaging; Hb: hemoglobin; LLN: lower lim\
it of normal; ULN: upper limit of normal; )18 (WBC: white bl)12.8 (ood cells; SLE: systemic)]TJ
0.0249 Tw T*
[(lupus erythematosus; )55 (ANA: antinuclear antibodies. H-2 blockers: histamine-2 blockers; FVC: fo\
rced vital capacity)65 (.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
0.5 w
54 720 m
558 720 l
54.53 160.4 m
559.33 160.4 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
74 0 obj
<>
endobj
196 0 obj
<>
endobj
53 0 obj
<>
endobj
57 0 obj
<>
endobj
19 0 obj
<>
endobj
27 0 obj
<>
endobj
28 0 obj
<>stream
HdVpTs͋р,!]/A-Y#)ȬnHu<H :
*"v| bPEZt4U5߹`?_}/){/pQo|oq`ΏlYo+x!`m|m_{w|:(PsӴ7@A A`hCc˲nrO{f5qݲ
K˚2#jPqEƺ/|_
70n>s%uMπlwhz,wuuV#m1VaoA|$NA'dz>zdg0q7ji?/hPKU0yJ~Pe[Yb_
wR=k[8O[17#ޭěserXU,Kv瞷Z6 M}纈0